The development and manufacture of influenza vaccines

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 6, 2015, Pages 1357-1360

  Buckland, Barry C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Flublok ; Hemagglutinin; Influenza; Vaccine manufacturing

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE;

ARTICLE; DRUG FORMULATION; HUMAN; IMMUNE RESPONSE; INFLUENZA; INFLUENZA VACCINATION; PROCESS DEVELOPMENT; ANIMAL; BIOTECHNOLOGY; ISOLATION AND PURIFICATION; PHARMACEUTICS; PROCEDURES;

ANIMALS; BIOTECHNOLOGY; HUMANS; INFLUENZA VACCINES; TECHNOLOGY, PHARMACEUTICAL;

EID: 84939781637     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1026497     Document Type: Article

References (8)

1. Josefsberg JO, Buckland B. Vaccine process technology. Biotechnol Bioeng 2012;109:1443-60; http://dx. doi. org/10. 1002/bit. 24493.
2. Cox MM, Hashimoto Y. A fast track influenza virus vaccine produced in insect cells. J Invertebr Pathol 2011;107(Suppl.):S31-4; PMID:21784229; http://dx. doi. org/10. 1016/j. jip. 2011. 05. 003.
3. Buckland Barry, Boulanger Robert, Fino M, Srivastava I, Holtz K, Khramtsov N, McPherson C, Meghrous J, Kubera P, Cox MM. Technology transfer and scale-up of the Flublok® recombinant hemagglutinin (HA) influenza vaccine manufacturing process Vaccine 2014; 32 5496-5502; PMID:25131727; http://dx. doi. org/ 10. 1016/j. vaccine. 2014. 07. 074.
4. Fedson DS, Dunnill P. New approaches to confronting an imminent influenza pandemic. Permanente J 2007; 11:63-9.
5. Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, Dickinson JA, Fonseca K, Winter AL, Gubbay JB, Krajden M, et al. Low 2012- 13 Influenza Effectiveness Associated with Mutation in the Egg Adapted H3N2 vaccine Strain Not Antigenic drift in circulating Viruses. 2014. PLOSone 2014; 9(3):e92153; DOI: 10. 1371/journal. pone. 0092153.
6. Butler D. Mutations explain poor showing of 2012 flu vaccine. Nature News; http://dx. doi. org/10. 1038/ nature. 2014. 14940
7. Treanor John J, El Sahly, Hana King J, Graham I, Izikson R, Kohberger R, Patriarca P, Cox M. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: A randomized, placebocontrolled trial. Vaccine 2011; 29: 7733- 7739; PMID:21835220; http://dx. doi. org/10. 1016/j. vaccine. 2011. 07. 128.
8. Friede M, Palkonyay L, Alfonso C, Pervikov Y, Torelli G, Wood D, et al. WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer. Vaccine 2011;29(Suppl. One):A2-7 [Review]; PMID:21684422; http://dx. doi. org/10. 1016/j. vaccine. 2011. 02. 079.